EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSPKIG00000006271
Gene Symbol: PIK3R5
3 Cross references
255 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSPKIG00000012237
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSPKIG00000022770
Gene Symbol: LOC111836863
3 Cross references
231 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSPKIG00000010876
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSPKIG00000001615
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSPKIG00000014490
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSPKIG00000009936
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Platelet-Derived Growth Factor Subunit B-Like

Ensembl ID : ENSPKIG00000001379
Gene Symbol: LOC111846386
2 Cross references
196 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSPKIG00000018828
Gene Symbol: PLK1
3 Cross references
140 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSPKIG00000013123
Gene Symbol: PLK1
4 Cross references
187 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSPKIG00000014404
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSPKIG00000006039
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).